ConductScience.org, home

Paper17560621

Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

Derby NR and 8 others. Virology, 2007. Cited by 22 papers, by iCite.

Cite this record

ConductScience Library. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens. Papers, record 17560621. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17560621

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.
PubMed
Journal
Virology
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
0.56
iCite
Revised in PubMed
2025-05-29
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Derby NRNina R
2Gray SSean
3Wayner EElizabeth
4Campogan DDwayne
5Vlahogiannis GGiorgos
6Kraft ZZane
7Barnett SWSusan W
8Srivastava IKIndresh K
9Stamatatos LLeonidas

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antibodies, ViralMajor topic
Gene Products, envMajor topic
HIV-1Major topic
Amino Acid Sequence
Animals
Cross Reactions
Epitope Mapping
Glycosylation
HIV Envelope Protein gp41
Mice
Molecular Sequence Data
Neutralization Tests
env Gene Products, Human Immunodeficiency Virus

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
T32 AI007509NIAID NIH HHSUnited StatesT32AI007509PubMed and NIHNIH RePORTER
R01 AI47708NIAID NIH HHSUnited StatesR01AI047708PubMed and NIHNIH RePORTER
P30 AI027757NIAID NIH HHSUnited StatesP30AI027757PubMed and NIHNIH RePORTER
AI007509NIAID NIH HHSUnited StatesT32AI007509PubMed and NIHNIH RePORTER
P30 AI27757NIAID NIH HHSUnited StatesP30AI027757PubMed and NIHNIH RePORTER
R01 AI047708NIAID NIH HHSUnited StatesR01AI047708PubMed and NIHNIH RePORTER

Download CSV of grants

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116809318
Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
J Virol2006https://conductscience.org/library/papers/16809318PubMed
29032336Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence.J Virol1997https://conductscience.org/library/papers/9032336PubMed
316920175Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.Virology2006https://conductscience.org/library/papers/16920175PubMed
417046088Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope.J Microbiol Methods2007https://conductscience.org/library/papers/17046088PubMed
510890360Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.AIDS Res Hum Retroviruses2000https://conductscience.org/library/papers/10890360PubMed
610888615
V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
J Virol2000https://conductscience.org/library/papers/10888615PubMed
711069996The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.J Virol2000https://conductscience.org/library/papers/11069996PubMed
811134278Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.J Virol2001https://conductscience.org/library/papers/11134278PubMed
911152489Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.J Virol2001https://conductscience.org/library/papers/11152489PubMed
1011356960
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
J Virol2001https://conductscience.org/library/papers/11356960PubMed
1111485624Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.AIDS Res Hum Retroviruses2001https://conductscience.org/library/papers/11485624PubMed
1211602729Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.J Virol2001https://conductscience.org/library/papers/11602729PubMed
1311997472Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.Proc Natl Acad Sci U S A2002https://conductscience.org/library/papers/11997472PubMed
1412551968Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.J Virol2003https://conductscience.org/library/papers/12551968PubMed
1512646921Antibody neutralization and escape by HIV-1.Nature2003https://conductscience.org/library/papers/12646921PubMed
1614512572
Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.
J Virol2003https://conductscience.org/library/papers/14512572PubMed
1714963123Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras.J Virol2004https://conductscience.org/library/papers/14963123PubMed
1815016849N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.J Virol2004https://conductscience.org/library/papers/15016849PubMed
1915039757Identifying epitopes of HIV-1 that induce protective antibodies.Nat Rev Immunol2004https://conductscience.org/library/papers/15039757PubMed
2015113902The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.J Virol2004https://conductscience.org/library/papers/15113902PubMed

See all 46 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
26039641Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.PLoS One2015https://conductscience.org/library/papers/26039641PubMed
25210191Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.J Virol2014https://conductscience.org/library/papers/25210191PubMed
25043633Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.Eur J Immunol2014https://conductscience.org/library/papers/25043633PubMed
24884925Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers.Retrovirology2014https://conductscience.org/library/papers/24884925PubMed
24872518Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.Clin Vaccine Immunol2014https://conductscience.org/library/papers/24872518PubMed
24828352Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.PLoS One2014https://conductscience.org/library/papers/24828352PubMed
22993152Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.J Virol2012https://conductscience.org/library/papers/22993152PubMed
21430056Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.J Virol2011https://conductscience.org/library/papers/21430056PubMed
21249232Characteristics of the earliest cross-neutralizing antibody response to HIV-1.PLoS Pathog2011https://conductscience.org/library/papers/21249232PubMed
20660181Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.J Virol2010https://conductscience.org/library/papers/20660181PubMed
20510738Emerging studies of human HIV-specific antibody repertoires.Vaccine2010https://conductscience.org/library/papers/20510738PubMed
20053749Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.J Virol2010https://conductscience.org/library/papers/20053749PubMed
19744690Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins.Virology2009https://conductscience.org/library/papers/19744690PubMed
19494007Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype.J Virol2009https://conductscience.org/library/papers/19494007PubMed
18804254Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.Virology2008https://conductscience.org/library/papers/18804254PubMed
18495775Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination.J Virol2008https://conductscience.org/library/papers/18495775PubMed
18003732
The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
J Virol2008https://conductscience.org/library/papers/18003732PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERVK-20100616444PubTator's text mininghttps://conductscience.org/library/genes/100616444NCBI Gene
ITIH43700PubTator's text mininghttps://conductscience.org/library/genes/3700NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17560621

GET https://conductscience.org/api/papers/v1/17560621/references?page=2